Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

For $85 million up-front in a deal potentially worth $480 million, Abbott gets a mid-stage antibody that could be a possible successor to strong-selling Humira.
Advertisement

Related Content

Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Abbott Shaves U.S. Pharma Costs With Restructuring
AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
Facet Says Yes To Abbott's $720 Million Buyout Offer

Topics

Advertisement
UsernamePublicRestriction

Register

PS072403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel